☆ 4.6 Article

Case Report: A Pancreatic Ductal Adenocarcinoma Patient With Concurrent Targetable Somatic Novel KANK1-ALK, UPP2-NTRK3 Fusion, and Pathogenetic Germline BRCA Mutation

FRONTIERS IN ONCOLOGY (2021)

Related references

Note: Only part of the references are listed.

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

Intergenic Breakpoints Identified by DNA Sequencing Confound Targetable Kinase Fusion Detection in NSCLC

Weihua Li et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

David S. Hong et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib

Arjan Gower et al.

JCO PRECISION ONCOLOGY (2020)

Add to Collection

Article Oncology

NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma

Martin R. Jones et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection

Article Medicine, General & Internal

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Talia Golan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Oncology

Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion

E. M. O'Reilly et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Oncology

Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma

Aatur D. Singhi et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)

Add to Collection

Article Medicine, General & Internal

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

Toyoaki Hida et al.

LANCET (2017)

Add to Collection

Article Oncology

Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma

Andrew J. Aguirre et al.

CANCER CELL (2017)

Add to Collection

Article Genetics & Heredity

InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP Guidelines

Quan Li et al.

AMERICAN JOURNAL OF HUMAN GENETICS (2017)

Add to Collection

Review Medicine, General & Internal

Pancreatic cancer

Terumi Kamisawa et al.

LANCET (2016)

Add to Collection

Article Biochemistry & Molecular Biology

VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research

Zhongwu Lai et al.

NUCLEIC ACIDS RESEARCH (2016)

Add to Collection

Article Biochemical Research Methods

FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution

Aaron M. Newman et al.

BIOINFORMATICS (2014)

Add to Collection

Article Oncology

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

Lola Rahib et al.

CANCER RESEARCH (2014)

Add to Collection

Article Medicine, General & Internal

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

Alice T. Shaw et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection

© Peeref 2019-2024. All rights reserved.